Tempus AI (NASDAQ:TEM) COO Sells $321,300.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $64.26, for a total value of $321,300.00. Following the transaction, the chief operating officer owned 148,808 shares of the company’s stock, valued at approximately $9,562,402.08. This represents a 3.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 1st, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The shares were sold at an average price of $75.72, for a total transaction of $378,600.00.
• On Tuesday, November 18th, Ryan Fukushima sold 10,099 shares of Tempus AI stock. The stock was sold at an average price of $65.54, for a total transaction of $661,888.46.
• On Monday, November 3rd, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The shares were sold at an average price of $89.03, for a total transaction of $445,150.00.

Tempus AI Trading Up 0.3%

Shares of NASDAQ TEM traded up $0.23 during midday trading on Wednesday, hitting $69.77. 4,128,129 shares of the company traded hands, compared to its average volume of 5,473,260. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $104.32. The firm has a market cap of $12.41 billion, a P/E ratio of -58.63 and a beta of 5.22. The stock has a 50-day moving average price of $71.46 and a 200 day moving average price of $73.38. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business had revenue of $334.21 million during the quarter, compared to analyst estimates of $328.89 million. During the same period last year, the business posted ($0.46) earnings per share. Tempus AI’s quarterly revenue was up 84.7% compared to the same quarter last year. As a group, analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

TEM has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. Piper Sandler reduced their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Canaccord Genuity Group lowered their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. Needham & Company LLC upped their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Tempus AI presently has a consensus rating of “Hold” and an average target price of $84.00.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently bought and sold shares of the company. Salem Investment Counselors Inc. grew its stake in shares of Tempus AI by 8,020.0% in the second quarter. Salem Investment Counselors Inc. now owns 30,450 shares of the company’s stock worth $1,935,000 after acquiring an additional 30,075 shares during the period. Renaissance Capital LLC boosted its holdings in Tempus AI by 26.9% in the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after purchasing an additional 17,866 shares during the last quarter. Pier 88 Investment Partners LLC bought a new stake in Tempus AI in the 2nd quarter worth approximately $286,000. Strs Ohio purchased a new stake in Tempus AI during the 1st quarter valued at $1,718,000. Finally, Blair William & Co. IL raised its stake in Tempus AI by 109.2% during the 2nd quarter. Blair William & Co. IL now owns 67,637 shares of the company’s stock valued at $4,298,000 after buying an additional 35,303 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.